STOCK TITAN
  1. Home
  2. Sec-filings
  3. UNCY
  4. [Form 4/A] Unicycive Therapeutics, Inc. Amended Insider Trading Activity

Unicycive Therapeutics (UNCY) director receives sizeable new RSU awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics director Sara Kenkare-Mitra received two new restricted stock unit (RSU) awards as equity compensation. On May 14, 2026, she was granted 42,100 RSUs and a separate 84,200 RSU annual award, each payable solely in common stock.

For the 42,100-unit RSU award, 11,694 shares vest immediately, with 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to her continued service. For the 84,200-unit annual RSU award, 17,542 shares vest upon grant and 3,508 vest monthly over 7 months starting the same date.

Positive

  • None.

Negative

  • None.
Insider Kenkare-Mitra Sara
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 84,200 $0.00 --
Grant/Award Restricted Stock Units 42,100 $0.00 --
Holdings After Transaction: Restricted Stock Units — 84,200 shares (Direct, null)
Footnotes (1)
  1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
RSU grant size 42,100 units Restricted Stock Units granted on May 14, 2026
Annual RSU award size 84,200 units Annual Restricted Stock Units granted on May 14, 2026
Immediate vesting from RSU Award 11,694 shares Portion of 42,100-unit RSU award vesting upon grant
Monthly vesting from RSU Award 2,339 shares/month Over 31 months starting June 1, 2026, for 42,100-unit award
Immediate vesting from Annual RSU 17,542 shares Portion of 84,200-unit annual RSU award vesting upon grant
Monthly vesting from Annual RSU 3,508 shares/month Over 7 months starting June 1, 2026, for annual RSU award
Holdings after first RSU grant 126,300 units Total restricted stock units following 42,100-unit award
Holdings after annual RSU grant 84,200 units Total restricted stock units following 84,200-unit annual award
Restricted Stock Units financial
"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSU Award financial
"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"
Annual RSU Award financial
"Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock"
vest financial
"11,694 shares vest upon grant and 2,339 vest monthly over 31 months"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kenkare-Mitra Sara
(Last)(First)(Middle)
C/O UNICYCIVE THERAPEUTICS, INC.
1975 W. EL CAMINO REAL, SUITE 204
(Street)
MOUNTAIN VIEW CALIFORNIA 94040
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
05/21/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$005/14/2026A84,200 (1) (1)Common Stock84,200$084,200D
Restricted Stock Units$005/14/2026A42,100 (2) (2)Common Stock42,100$0126,300D
Explanation of Responses:
1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
2. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
/s/ Sara Kenkare-Mitra06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did UNCY director Sara Kenkare-Mitra report?

Sara Kenkare-Mitra reported receiving two restricted stock unit awards. On May 14, 2026, she was granted 42,100 RSUs and a separate 84,200-unit annual RSU award, both payable in Unicycive Therapeutics common stock as part of her equity compensation.

How many restricted stock units did UNCY grant in total to the director?

The director received RSU grants of 42,100 units and 84,200 units. Each grant is structured as restricted stock units payable solely in Unicycive Therapeutics common stock, with portions vesting immediately and the remainder vesting monthly over specified periods.

What is the vesting schedule for Sara Kenkare-Mitra’s 42,100-unit RSU award at UNCY?

The 42,100-unit RSU award vests over roughly 32 months. According to the filing, 11,694 shares vest upon grant, and 2,339 shares vest monthly over 31 months beginning June 1, 2026, contingent on her continued service with Unicycive Therapeutics.

How do the annual RSU awards for UNCY’s director vest over time?

The 84,200-unit annual RSU award vests in two phases. Footnotes state 17,542 shares vest upon grant, and 3,508 shares vest monthly over 7 months starting June 1, 2026, provided Sara Kenkare-Mitra continues serving the company.

Are the UNCY restricted stock unit awards paid in cash or stock?

Both awards are payable solely in Unicycive common stock. The filing specifies each restricted stock unit grant, including the annual RSU award, will settle in shares of the company’s common stock as vesting conditions are satisfied.

Does this UNCY Form 4/A reflect open-market buying or selling?

No, the transactions are equity compensation grants, not market trades. The Form 4/A lists RSU awards coded as "A" for grant or award acquisition, with a price per unit of $0.0000, indicating non-cash, compensation-related issuances.